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years. In their study of 1399 patients
undergoing AVR, PPM had a negative
effect on late survival for patients
younger than 70 years but did not in-
fluence late survival in patients older
than 70 years.
Mohty and associates2 similarly
found that AVR, with either a biopros-
thesis or a mechanical valve, does not
increase late mortality in patients older
than 70 years. As Moon and col-
leagues1 outline in their discussion of
the study’s limitations, they do not ad-
dress the effects on late functional state
or left ventricular mass regression, and
moreover, they do not mention quality
of life (QOL).
In my opinion, it is very important to
consider a good QOL as a goal for most
operations. Especially in the elderly
population, it is important to maintain
or improve QOL in addition to pro-
longing life. Koch and coworkers5
found that factors other than prosthe-
sis/patient size ratio influence func-
tional QOL after AVR. Yamaguchi
and colleagues6 suggested that im-
provement in QOL can be expected af-
ter heart valve replacement in patients
older than 70 years. However, their
study population was different from
that of Moon and colleagues1 and in-
cluded mechanical and bioprosthetic
valves placed in multiple positions; ad-
ditionally, we do not know whether the
PPM occurred in the AVRs in the se-
ries of Yamaguchi and colleagues.6
PPM affects left ventricular remod-
eling, surgical outcome, and late mor-
tality, and therefore should be
considered a diseased state.2 It is im-
portant to know whether PPM in el-
derly patients influences recovery
after AVR.
If Moon and colleagues1 have data
about the QOL of their 1399 patients,
the information derived from these
data could help us understand how
PPM affects QOL and would be highly
relevant in the care of elderly patients
undergoing AVR.
Stefano Salizzoni, MD
Division of Cardiothoracic Surgery–
Heart, Lung and Esophageal Surgery
Institute
University of Pittsburgh Medical
Center
Pittsburgh, Pa
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Letters to the Editor
The JournPROSTHESIS–PATIENT
MISMATCH DOES NOTAFFECT
SURVIVAL AND QUALITY OF
LIFE IN THE ELDERLY HAVING
BILEAFLET PROSTHESES
IMPLANT
To the Editor:
We read with interest the article by
Moon and colleagues evaluating the
impact of prosthesis–patient mismatch
(PPM) on the long-term outcomes for
elderly patients having aortic valve
replacement (AVR).1 The study evi-
denced the lack of influence on sur-
vival by PPM after implantation of
biologic prostheses in elderly people.
We would be interested to learn
from the authors whether they evalu-
ated the impact of PPM on incidence
of bioprosthesis degeneration at fol-
low-up.al of Thoracic and Cardiovascular SurgWe agree with authors’ consider-
ation, discussed in the Comment sec-
tion, of the inopportunity of aortic
root enlargement in this subset of
patients, and we also support the iso-
lated AVR for aortic stenosis.
We recently have published a series
on the topic of PPM and reported com-
parable conclusions.2,3 However, we
would like to share with the authors
our different policy regarding the
choice of mechanical prostheses, and
we would like to receive their consid-
eration about this.
In our view, the increased life
expectancy has increased the risk of
reoperation for structural degeneration
of a bioprosthesis during long-term
follow-up. Life expectancy in septua-
genarians can be 14 to 15 years, and
the durability of a bioprosthesis could
be inferior despite the engineering im-
provements. To reduce the probability
of reoperation in the eighth or ninth
decade of life, we apply precise selec-
tive criteria to the choice of biologic or
mechanical prosthesis.
As reported in our previous stud-
ies,4,5 the choice of prosthetic implants
for old patients was fundamentally
guided by the consideration of pa-
tient’s biologic age and associated
with the foreseeable life expectancy.
We chose mechanical devices for
elderly patients who reasonably had
a life expectancy of more than 10 to
12 years. Moreover, patients already
receiving long-term anticoagulation
for chronic atrial fibrillation were
offered a mechanical prosthesis. Bio-
logic prostheses were preferred for
those patients with contraindication
to oral anticoagulation or those in
whom general senescence status or
associated multiple noncardiac comor-
bidities, or both, suggested a life
expectancy of less than 10 years. The
incidence of anticoagulation-related
complications is very low, with a free-
dom from hemorrhagic event of
96.9%  0.013% at 10 years.
Our institution includes an outpa-
tient clinic that monitors anticoagula-
tion therapy in a number of elderlyery c Volume 138, Number 3 787
Reply to the Editor:
I would like to thank the groups from
Naples and Pittsburgh for their interest
in our recent study examining the im-
pact of prosthesis–patient mismatch
(PPM) on long-term survival in pa-
tients greater than 70 years of age. It
is important to note that we did not
specifically investigate the role of
PPM on tissue valve degeneration,
but it is likely to play a role given the
potential impact of pressure gradients
on leaflet durability. However, as dem-
onstrated by Fann and associates from
Stanford,1 age clearly impacts the rate
of structural valve degeneration, such
that even with first- and second-gener-
ation prostheses, freedom from struc-
tural failure at 15 years exceeds 90%
in patients over 70 years of age. It is
our hope that newer prostheses with
anticalcification treatments, low pres-
sure fixation, and better flow character-
istics yielding lower transvalvular
gradients will demonstrate increased
long-term durability, but only time
will tell.
I think we all agree that the popula-
tion is growing older and living longer
across the globe. For example, in the
United States, life expectancy has in-
creased from 67 years for men and 75
years for women in 1970 to 75 years
for men and 80 years for women in
2005,2 a change that would, in and of
itself, shift the crossover age rightward
for recommending a mechanical over
biologic valve during aortic valve
replacement (AVR). At the same
time, however, lifestyle issues, at least
among my patient population, have be-
come increasingly important with the
desire to avoid lifelong warfarin more
appealing than a potential one-time
‘‘AVR-for-life.’’ This has led to an in-
creasing percentage of well-educated
patients in their 50s, 40s, and even
30s and 20s, selecting bioprosthetic
over mechanical valves, at least in the
aortic position. We do agree that, al-
though a redo AVR in a 40- or 50-
year-old patient carries little risk,
a redo in an 85- or 90-year-old patient
is a much less desirable proposition.
Vicchio and colleagues3 have devel-
oped a well-structured algorithm for
selecting biologic versus mechanical
prostheses in elderly patients, facili-
tated, no doubt, by their institution’s
outpatient anticoagulation monitoring
program, which boasts (appropriately
so) a very low incidence of bleeding
complications in elderly patients.
An additional shortcoming of our
study is that it did not assess the impact
of PPM on functional status or quality of
life. In a previous study from our unit,
we found that quality of life following
AVR in octogenarians, quantified using
the Medical Outcomes Study Short
Form-36, was similar to the age-
matched general population, but we
did not assess the independent impact
of PPM.4 Clearly, there are patients
who will benefit from the presence of
a diminished gradient over time. How-
ever, it remains my contention that, al-
though it is important to avoid PPM in
younger patients by either enlarging
the root or implanting a prosthesis
with favorable flow characteristics, el-
derly patients with limited preoperative
functional status or significant comor-
bidities are better served with a ‘‘get in
and get out’’ approach during AVR.
Marc R. Moon, MD
Joseph C. Bancroft Professor of
Surgery
Division of Cardiothoracic Surgery
Washington University School of
Medicine
Saint Louis, Mo
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Letters to the Editorpatients. A medical team updates the
anticoagulation therapy for each
patient following a uniform protocol
of anticoagulation. In our experience,
the use of anticoagulation in elderly
people is safe, and quality of life is
not negatively influenced by check of
international normalized ratio.
On this basis, we have reported
our results in terms of impact of
PPM (moderate, severe, or absent)
on survival in elderly people receiv-
ing mechanical prostheses implants.
In our series, the incidence of severe
PPM during the follow-up was very
low. The presence of severe or mod-
erate PPM did not influence long-
term outcome, left ventricular mass
regression, and quality of life in
a population of septuagenarians. On
the basis of our experience, we use
isolated aortic valve replacement
with a mechanical prosthesis, which
represents a judicious alternative in
elderly people to bioprosthesis im-
plant.
Mariano Vicchio, MD, PhD
Marisa De Feo, MD, PhD
Maurizio Cotrufo, MD
Department of Cardiothoracic
Sciences
Second University of Naples
Department of Cardiovascular
Surgery and Transplants
V. Monaldi Hospital
Naples, Italy
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